Abstract| Volume 92, SUPPLEMENT 1, S16-S17, March 2018

Download started.


Peritumoral gene electrotransfer of interleukin-12 as an adjuvant immunotherapy to intratumoral electrochemotherapy for murine melanoma treatment

      Background: Combining established therapies with recently discovered immunotherapies is a promising approach for treating malignant melanoma. Our research group has been studying intratumoral electrochemotherapy (a combination of a chemotherapeutic drug and electroporation), which is a well-established therapy in clinics across Europe [1]. Besides local release or exposition of damage-associated molecular patterns and neoantigens, electrochemotherapy with cisplatin, oxaliplatin or bleomycin induces immunogenic cell death [2, 3]. Although local effectiveness of electrochemotherapy is up to 80 % of local tumor control, no noticeable effects on distant non-treated metastases have been observed [1]. We hypothesized that gene electrotransfer of plasmid encoding for interleukin-12 (IL-12) as an adjuvant immunotherapy, compliments the responses seen with electrochemotherapy on a local and systemic level.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect